Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Eye disorders – page 14

  • 369 clinical trials
  • 123 recruiting
  • 134 conditions
  • 27 countries

Conditions in this area

134 conditions with trials, the busiest first

Conjunctivitis allergic34Sjogren's syndrome29Endocrine ophthalmopathy26Neovascular age-related macular degeneration23Giant cell arteritis18Seasonal allergy17Uveal melanoma17Rhinitis allergic16Dry age-related macular degeneration15Diabetic retinal oedema13Dry eye12Retinitis pigmentosa11Age-related macular degeneration10Asthma10Graves' disease10Myopia10Glaucoma8Open angle glaucoma8Uveitis8Immunoglobulin G4 related disease7Behcet's syndrome6Cataract6Mite allergy6Rheumatoid arthritis6+110

Clinical trials in Eye disorders

369 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

369 clinical trials

Endocrine ophthalmopathy

Not yet recruiting

Study Using Gallium-68 FAPI PET/MRI Imaging to Measure Disease Activity in Patients with Graves' Eye Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Retinal dystrophy

Not yet recruiting

Safety and early effectiveness study of VG801 subretinal injection in patients with ABCA4 mutation-associated retinal dystrophy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:VG801-1
  • Sponsor:VeonGen Therapeutics GmbH

Systemic lupus erythematosus+6

Not yet recruiting

Study of RSV vaccines Arexvy and Abrysvo in patients with inflammatory rheumatic diseases receiving anti-rheumatic treatments

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:Region Skane

Giant cell arteritis

Not yet recruiting

Study of bosentan, prednisone and prednisolone in patients with newly diagnosed or relapsing giant cell arteritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bosentan
  • Sponsor:Assistance Publique Hopitaux De Paris

Dry eye

Not yet recruiting

Evaluation of Mesenchymal Stem Cell Eye Injections for Dry Eye Disease in Patients with Graft-versus-Host Disease Who Haven't Responded to Standard Treatments

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Adipose-Derived Adult Mesenchymal Stem Cells Expanded
  • Sponsor:Fundacion De Investigacion Biomedica De Salamanca

Neovascular age-related macular degeneration

Not yet recruiting

Long-term Safety and Effectiveness Evaluation of RGX-314 in Patients with Neovascular Age-related Macular Degeneration

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Eye inflammation+1

Not yet recruiting

Study on Reducing Eye Prosthesis Discomfort and Discharge Using Retinol Palmitate, Fluorometholone, and Artificial Tears for Patients with Chronic Eye Socket Issues

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Fluorometholone
  • Sponsor:Amsterdam UMC Stichting

Seasonal allergy

Not yet recruiting

Study to Find the Best Dose of Beltavac with Grass Pollen Extract for Patients with Allergic Rhinoconjunctivitis, with or without Asthma

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Probelte Pharma S.L.

Dry eye

Not yet recruiting

Study on the Use of PRGF Eye Drops for Treating Dry Eye Disease in Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Hypromellose
  • Sponsor:Biotechnology Institute I Mas D S.L.

Rheumatoid arthritis+1

Not yet recruiting

Study on the Safety and Effects of Rapcabtagene Autoleucel, Tocilizumab, Fludarabine Phosphate, and Cyclophosphamide for Patients with Rheumatoid Arthritis and Sjogren's Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Endocrine ophthalmopathy

Not yet recruiting

Study on the Effects of TOUR006 for Adults with Thyroid Eye Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN IGG2 MONOCLONAL ANTIBODY AGAINST IL-6
  • Sponsor:Tourmaline Bio Inc.

Retinitis pigmentosa

Not yet recruiting

Study on the Effectiveness and Safety of Ultevursen for Patients with Retinitis Pigmentosa Due to USH2A Gene Mutations

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ULTEVURSEN
  • Sponsor:Laboratoires Thea

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Aflibercept27 clinical trialsSodium Chloride16 clinical trialsPrednisone14 clinical trialsRanibizumab14 clinical trialsDexamethasone11 clinical trialsDexamethasone Phosphate10 clinical trialsFluorescein Sodium10 clinical trialsPrednisolone10 clinical trialsNivolumab8 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.